Lamictal (lamotrigine) is successful at controlling a broad range of seizure disorders. It was first approved as adjunctive (add-on) therapy for adults with partial epilepsy, but now it is also approved for use by children over 2 years of age. Lamictal is also one of the few drugs approved by the U.S. Food and Drug Administration (FDA) as adjunctive therapy for the Lennox-Gastaut syndrome in children and adults. In September of 2006, Lamictal was approved as add-on therapy for primary generalized tonic-clonic seizures in adults and children 2 years and older. It is also used for atonic seizures, and juvenile myoclonic epilepsy syndromes.

Lamictal is also approved by the FDA when withdrawn to monotherapy for the treatment of partial seizures. This means that if someone already taking another seizure medicine starts taking Lamictal, then the first medicine can be gradually stopped, leaving the person taking Lamictal by itself.

Last updated: 09/26/2006